Company intelligence / Profile preview
Tollys
Lyon, Francetollys.fr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tollys is advancing preclinical RNA immunotherapies targeting TLR3 for cancer treatment, with lead candidate TL-532 planned for bladder cancer clinical trials.
- Therapeutic areas
- OncologyImmunology
- Modalities
- RNA therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Tollys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tollys.